A 6-week randomized trial found that tirzepatide significantly reduced energy intake, appetite, and cravings in adults with ...

India's anti-obesity drug market is currently valued at Rs 3,000-3,500 crore & is projected to grow nearly eightfold by 2030, ...

People seeking weight-loss medication on the NHS are being warned it is not yet available in Derbyshire and only a very ...

A new review suggests that tirzepatide (Mounjaro, Zepbound) may have neuroprotective mechanisms that could help reduce the ...

Boots Online Doctor has revealed the 'very common' side-effects of Mounjaro you need to know about after thousands of people ...

Eli Lilly’s tirzepatide is expected to be worth $62 billion annually by 2030, according to Evaluate. That valuation would be ...

GLP-1 obesity drug use is rising, but long-term adherence remains low. While one-year persistence has improved in 2024, only ...

GoodRx reports GLP-1 weight-loss pills are emerging, with candidates like orforglipron and oral semaglutide likely to gain FDA approval by 2026.

The once-monthly drug is still under study but could provide added convenience and another option for patients.

Signs of advanced chronic pancreatitis include weight loss, a loss of appetite, jaundice, other symptoms associated with ...

Scholar Rock's Apitegromab excels in Phase 2 trials, aiding muscle preservation with Tirzepatide. Click here to read why I ...

The NHS has just announced a major change made to Mounjaro access as 1,600,000 people are now expected to receive the weight ...